Furthermore, Liraglutide led to a decrease of TGF-β1 levels when added to cells exposed to hyperglycemia and/or oxidative stress, suggesting that the protective effect of Liraglutide was mediated through the inhibition of TGF-β1 expression in this model of diabetic nephropathy. This evidence concerns the gene TGFB1 and diabetic kidney disease.